“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:  Orphan Cancer Drug Market Outlook  Orphan Drug Designation Criteria: US, Europe & Asia  Reimbursement Policy: US, Europe & Asia  Regulatory Framework: FDA & EMA Guidelines  Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications  Orphan Cancer Drug Patent Analysis  Orphan Cancer Drug in Development Phase: 235  Majority of Orphan Cancer Drugs in Phase-II: 81  Marketed Orphan Cancer Drugs: 70

1. Cancer Drugs Dominating Global Orphan Drug Market Landscape
Orphan designated cancer drugs accounts for average 40% of total orphan drug market.
“Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights:
 Orphan Cancer Drug Market Outlook
 Orphan Drug Designation Criteria: US, Europe & Asia
 Reimbursement Policy: US, Europe & Asia
 Regulatory Framework: FDA & EMA Guidelines
 Orphan Cancer Drugs Clinical Pipeline by Phase, Country & Target Indications
 Orphan Cancer Drug Patent Analysis
 Orphan Cancer Drug in Development Phase: 235
 Majority of Orphan Cancer Drugs in Phase-II: 81
 Marketed Orphan Cancer Drugs: 70
The orphan drugs enjoy significant competitive advantages in the market owing to the market
exclusivity period after the drug has been authorized. Through this clause, the manufacturer
of orphan drugs is given a monopoly status in the market because according to the law, no
other company is allowed to market the orphan drugs during the exclusivity period.
Additionally, this monopolistic power is further strengthened with the fact that no other
alternative health technology exists for many orphan drugs.
The segment which generated the largest amount of revenues in 2013 was orphan drugs for
the oncology sector, which accounts for approximately 40%. A major reason for such a high
level of concentration on oncology particularly is that the underlying genetic aberration of
oncology generally helps in the process of identification of the disease. Oncology, as a
therapeutic area has also transformed from evolution to customized or precision medicine in
the pharmaceutical industry. Utilizing biomarkers to develop targeted treatments and
therapies is an approach which is being increasingly used in recent years, which also further
explains the reasons behind this therapeutic area’s majority share of orphan drug approvals.
With the oncology pipeline for orphan drugs being very promising, it is expected that over the
next few years, many drugs are likely to be developed over a range of indications including
the commonly diagnosed lung and colorectal cancer types. With the introduction of these

2. products in the market, it is likely that there would be a significant improvement in the
survival rates of the patients.
For Report Sample visit: Global Orphan Cancer Drug Market & Clinical Pipeline
Insight
or Contact: avinash@kuickresearch.com